PCMA Applauds the Senate Judiciary Committee’s Approval of Prescription Drug Pricing Legislation to Promote Greater Competition, Lower Prescription Drug Costs

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) Chief Policy and External Affairs Officer Kristin Bass released the following statement on the legislative markup on prescription drug pricing legislation by the U.S. Senate Committee on the Judiciary.

“We applaud members of the Senate Judiciary Committee for recognizing that greater competition in the prescription drug market will lead to lower prescription drug costs for patients. The advancement of these bills will help to further limit common and egregious anti-competitive practices used to unfairly extend monopolies, and encourage greater competition and investment in more affordable options, like biosimilars, for patients.

PCMA commends Chairman Durbin, Ranking Member Graham, and members of the Committee for bringing these important solutions forward.”

PCMA supports the following legislation:

  1. S. 79, Interagency Patent Coordination and Improvement Act of 2023
  2. S. 113, Prescription Pricing for the People Act of 2023
  3. S. 142, Preserve Access to Affordable Generics and Biosimilars Act
  4. S. 148, Stop STALLING Act
  5. S. 159, Affordable Prescriptions for Patients Act of 2023

Read PCMA’s statement on the reintroduction of the Affordable Prescriptions for Patients Act HERE.

Read more on how greater biosimilar competition can help lower prescription drug costs for patients HERE.

Read more on the cost of big drug companies’ patent thickets HERE.

Read more on the cost of big drug companies’ product hopping HERE.


PCMA is the national association representing America’s pharmacy benefit companies. Pharmacy benefit companies are working every day to secure savings, enable better health outcomes, and support access to quality prescription drug coverage for more than 275 million patients.